Royalty Pharma, plc (RPRX) Rallied on Earnings Beat

Royalty Pharma, plc (RPRX) Rallied on Earnings Beat Soumya Eswaran Mon, June 29, 2026 at 8:16 PM GMT+7 3 min read RPRX ^GSPC CBOE CL=F Meridian Funds, managed by Arrow Mark Partners, released its first-quarter 2026 investor letter for "Meridian Hedged Equity Fund". A copy of the letter can be downloaded here. The Fund invests in high-quality growth companies and mitigates risk by writing call options. Following the late-February strike on Iran, oil prices surged, leading to a risk-off sentiment, boosting energy sector performance. Large-cap technology stocks declined as investors rotated towards smaller companies and more defensive value investments. Market conditions are becoming challenging due to reduced expectations for a Federal Reserve rate cut and increasing geopolitical uncertainty. The Fund returned 0.08% (net) for the quarter, outperforming the S&P 500 Index, which fell 4.33%, and the CBOE S&P 500 BuyWrite Index, which declined 0.92%. At the end of the period, 43% of the portfolio was unhedged, while the remainder was invested in companies with covered call options. In addition, please check the Fund's top five holdings to know its best picks in 2026.

In its first-quarter 2026 investor letter, Meridian Hedged Equity Fund highlighted Royalty Pharma plc (NASDAQ:RPRX). Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical investment company that specializes in acquiring royalty interests and funding innovation in the biopharmaceutical industry. On June 26, 2026, Royalty Pharma plc (NASDAQ:RPRX) closed at $56.23 per share, reflecting a market capitalization of $32.38 billion. Royalty Pharma plc (NASDAQ:RPRX) posted a one-month return of 1.90%, and its shares gained 56.06% over the past 52 weeks.

Meridian Hedged Equity Fund stated the following regarding Royalty Pharma plc (NASDAQ:RPRX) in its Q1 2026 investor letter: